IHE News & Analysis

2 articles

Market Mood

1 Bullish1 Neutral0 Bearish
IHE vs PJP: Key ETF Metrics Include Expense Ratios and Dividends
ETFsNeutral7/5/2026

IHE vs PJP: Key ETF Metrics Include Expense Ratios and Dividends

The iShares U.S. Pharmaceuticals ETF (IHE) has an expense ratio of 0.38% and a dividend yield of 1.62%, while the Invesco Pharmaceuticals ETF (PJP) has a higher expense ratio of 0.57% and a dividend yield of 0.96%. IHE holds 56 positions, heavily concentrated in Eli Lilly (NYSE:LLY) at 24.2% and Johnson & Johnson (NYSE:JNJ) at 20.3%. In contrast, PJP features 29 companies with Eli Lilly at 5.4%. Investors' choice between IHE and PJP hinges on their comfort with company-specific risks within the pharmaceutical sector.

Read More: IHE vs PJP: Key ETF Metrics Include Expense Ratios and Dividends
IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison
MarketsBullish5/27/2026

IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison

The iShares U.S. Pharmaceuticals ETF (IHE) has posted a 1-year return of 39.70% as of May 20, 2026, while the iShares Global Healthcare ETF (IXJ) reported a return of 10.00%. Both funds have similar expense ratios, with IHE at 0.38% and IXJ at 0.40%. IHE's assets under management (AUM) stand at $883.6 million, compared to IXJ's $3.6 billion. Additionally, IHE has a higher dividend yield of 1.70% versus IXJ's 1.50%, indicating potential advantages for investors favoring domestic pharmaceutical exposure.

Read More: IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison